Developing Adrenocortical Carcinoma Patient-Derived Organoids to Identify Therapeutic Vulnerabilities
Abstract
Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. There are currently limited therapies for ACC that has spread beyond the adrenal gland to other parts of the body. The development of new treatments for ACC is, in part, hindered by the lack of research models that can be used in the laboratory to test new and existing drugs. In this project, we address the following Rare Cancer Research Program Focus Areas: Research Model and Therapy. We will obtain tumor samples from ACC patients undergoing surgery with the goal to develop new models called organoids. Organoids are tumor cells growing outside the living body in an artificial environment and allow for testing the effect of anti-cancer drugs in a more human-like environment. We will perform genomic analyses and test a large number of drugs on these organoids. The successful outcome of this research will allow us to create organoids that properly model ACC and identify drugs that can efficiently kill ACC cancer cells. We expect this work to lead to the clinical testing of new therapies for ACC patients.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2210658
Entities
People
- Nitin Roper
Organizations
- National Cancer Institute
- United States Army